Parnassus Investments’s BioMarin Pharmaceuticals BMRN Stock Holding History

Parnassus Investments’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-873,001	Closed	-$76.2M	–	131
2024 Q1	$76.2M	Sell	873,001 -976,347	-53%	-$87.4M	0.16%	89
2023 Q4	$178M	Sell	1,849,348 -489,181	-21%	-$43.3M	0.4%	51
2023 Q3	$207M	Hold	2,338,529	–	–	0.51%	46
2023 Q2	$203M	Hold	2,338,529	–	–	0.47%	46
2023 Q1	$227M	Hold	2,338,529	–	–	0.56%	46
2022 Q4	$242M	Sell	2,338,529 -227,551	-9%	-$21.4M	0.6%	43
2022 Q3	$218M	Sell	2,566,080 -215,340	-8%	-$19.2M	0.57%	45
2022 Q2	$230M	Buy	2,781,420 +55,490	+2%	+$4.42M	0.55%	47
2022 Q1	$210M	Hold	2,725,930	–	–	0.43%	52
2021 Q4	$241M	Buy	2,725,930 +41,056	+2%	+$3.39M	0.46%	54
2021 Q3	$208M	Hold	2,684,874	–	–	0.44%	55
2021 Q2	$224M	Hold	2,684,874	–	–	0.49%	50
2021 Q1	$203M	Buy	2,684,874 +1,165,923	+77%	+$95.2M	0.49%	50
2020 Q4	$133M	Buy	1,518,951 +1,331,882	+712%	+$106M	0.36%	62
2020 Q3	$14.2M	Buy	187,069 +97,349	+109%	+$9.85M	0.04%	101
2020 Q2	$11.1M	Buy	+89,720	New	+$8.92M	0.04%	104

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Parnassus Investments's BMRN Position: Q2 2024 in Review

Parnassus Investments sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2024, closing a stake of 873,001 shares — an estimated $76.2M sold.

Parnassus Investments first reported a position in BMRN in Q2 2020 and held it in 16 quarters. The position peaked at $242M in Q4 2022. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2024.

Parnassus Investments reported no remaining BioMarin Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Parnassus Investments sold 873,001 BioMarin Pharmaceuticals shares in Q2 2024, an estimated $76.2M.
Parnassus Investments first reported a position in BioMarin Pharmaceuticals in Q2 2020 and held it in 16 quarters.
Parnassus Investments's BioMarin Pharmaceuticals position peaked at $242M in Q4 2022.
558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2024.

Based on Parnassus Investments's 13F filing for Q2 2024, filed 6 Aug 2024.